← Eichor
Condition: Recurrent Nasopharyngeal Neoplasms Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Nasopharyngeal Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Phase 3 · 7 location(s) · Eye & ENT Hospital of Fudan University · NCT06228079Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
EARLY_Phase 1 · 1 location(s) · Fudan University · NCT05587543LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539Proton Therapy for Recurrent Nasopharyngeal Carcinoma
NA · 2 location(s) · Guangzhou Concord Cancer Center · NCT07412314Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
NA · 1 location(s) · Affiliated Hospital of Nantong University · NCT06389201A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT07277764Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06197776PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT03907826Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · 88 location(s) · National Cancer Institute (NCI) · NCT06029270A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/Phase 2 · 20 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07258979A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance
Phase 2 · 15 location(s) · Shanghai Henlius Biotech · NCT06839066Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Shanghai Institute Of Biological Products · NCT06194656Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic H
Phase 1 · 1 location(s) · West China Hospital · NCT07625423Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05340491EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06802835Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Me
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT06976190Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT07581821A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcin
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437522A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemothera
Phase 2/Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06241599Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06509009Deep Learning-based sbORN Diagnostic Model
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06463392Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06323239Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3 · 7 location(s) · Sun Yat-sen University · NCT04778956Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Phase 3 · 1 location(s) · Fudan University · NCT06177301
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.